A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia - Concepedia

Concepedia

Publication | Open Access

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia

DOI Full Paper Access

146

Citations

18

References

2021

Year

Eddy Fadlyana, Kusnandi Rusmil, Rodman Tarigan, Andri Reza Rahmadi, Susantina Prodjosoewojo, Yulia Sofiatin, Citra Vravita Khrisna, Rini Mulia Sari, Lilis Setyaningsih, Fikrianti Surachman,

Abstract

From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.

References

	Year	Citations

Page 1